Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=award_amount" }, "data": [ { "type": "Grant", "id": "10651", "attributes": { "award_id": "75N95022P00438-0-0-1", "title": "N3C OPEN DATA PORTAL AND COMMUNITY ENGAGEMENT SUPPORT SERVICES FOR NCATS (COVID-19 ACTION)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)", "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-02", "end_date": "2023-09-01", "award_amount": 3295541, "principal_investigator": { "id": 24128, "first_name": "SUHAS", "last_name": "SHARMA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides support for all of these enterprise IT efforts.", "keywords": [ "Area", "Award", "Businesses", "COVID-19", "COVID-19 patient", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Complex Analysis", "Contracts", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Development", "Electronic Health Record", "Ensure", "Environment", "Genomics", "Health", "Image", "Informatics", "Information Technology", "Ingestion", "National Center for Advancing Translational Sciences", "National Institute of General Medical Sciences", "Pathology", "Privacy", "Productivity", "Pythons", "Radiology Specialty", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Security", "Services", "Statistical Data Interpretation", "Translational Research", "United States", "United States National Institutes of Health", "Viral", "Visualization", "Work", "analytical tool", "cloud based", "cohort", "community engagement", "coronavirus disease", "data enclave", "data harmonization", "data portal", "genetic variant", "meetings", "multimodal data", "open data", "open source", "open source tool", "programs", "protective factors", "tool", "virtual" ], "approved": true } }, { "type": "Grant", "id": "10368", "attributes": { "award_id": "1RF1MH132360-01", "title": "Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depression", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 6350, "first_name": "Jennifer", "last_name": "Humensky", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 3296734, "principal_investigator": { "id": 21915, "first_name": "Denis", "last_name": "Nash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26340, "first_name": "Angela", "last_name": "Parcesepe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1070, "ror": "", "name": "GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Despite increased risk of COVID-19 infection, severe complications, hospitalizations, and death, people with mental health disorders report greater vaccine hesitancy and have lower COVID vaccination levels than the general population. Individuals with mental health disorders are much more likely to endorse COVID-19 vaccine misinformation, which may mediate the relationship between mental health and vaccine hesitancy. Interventions capable of mitigating the impact of vaccine hesitancy, mis/disinformation, and logistical barriers among unvaccinated people with mental health disorders are an urgent priority. Attitudinal inoculation is a brief, scalable strategy to address mis/disinformation. In a quasi-experimental trial, our team found that a brief online attitudinal inoculation intervention specifically addressing COVID-19 vaccine mis/disinformation significantly decreased COVID-19 vaccine hesitancy and increased resistance to vaccine misinformation among unvaccinated US adults. However, its effectiveness among individuals with mental health disorders is unknown. Informed by inoculation theory, attitudinal inoculation leverages the power of narrative, values, and emotion to strengthen resistance to misinformation and reduce hesitancy and is well- suited for low-information audiences and ideologically polarized or conspiratorial groups. The proposed research project will leverage the infrastructure of the national CHASING COVID Cohort, a large and geographically diverse community-based US cohort, to tailor and test the effectiveness of a brief digital attitudinal inoculation intervention to increase vaccination among adults with anxiety or depression symptoms. Aim 1: Characterize the relationship between symptoms of anxiety and depression and vaccine/booster uptake, and other related determinants of vaccine uptake (including endorsement of COVID-19 misinformation and vaccine hesitancy) among those with and without anxiety/depression Aim 2: Adapt and pilot an evidence-based attitudinal inoculation intervention to increase COVID-19 vaccination and boosting among adults with symptoms of anxiety or depression. Aim 3: Determine the effectiveness of two brief digital attitudinal inoculation intervention strategies compared with conventional public health messaging for increasing vaccine uptake in un/undervaccinated and unboosted adults. This study directly addresses the priorities of the National Institute of Mental Health and the PAR: COVID-19 Mental Health Research (PAR-22-112) to conduct “intervention effectiveness research to address vaccine hesitancy, uptake, and implementation among mental health populations.” This research will rapidly generate evidence to inform the development and implementation of strategies to increase vaccination uptake and mitigate the impact of COVID-19 among mental health populations. Beyond the COVID pandemic, this research has direct applicability to future pandemics and routine vaccination campaigns.", "keywords": [ "Address", "Adult", "Anxiety", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 risk", "COVID-19 vaccination", "COVID-19 vaccine", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Communities", "Data", "Development", "Effectiveness", "Effectiveness of Interventions", "Emotions", "Future", "General Population", "Geography", "Hospitalization", "Individual", "Infrastructure", "Intervention", "Interview", "Logistics", "Mediating", "Medical", "Mental Depression", "Mental Health", "Mental Health Services", "Mental disorders", "Misinformation", "Mood Disorders", "National Institute of Mental Health", "Participant", "Persons", "Positioning Attribute", "Prevalence", "Public Health", "Randomized", "Reporting", "Research", "Research Project Grants", "Resistance", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "Secondary Immunization", "Social support", "United States", "Vaccinated", "Vaccination", "Vaccines", "anxiety symptoms", "base", "booster vaccine", "cohort", "coronavirus disease", "depressive symptoms", "digital", "digital intervention", "effectiveness evaluation", "effectiveness research", "effectiveness testing", "evidence base", "experience", "high risk", "mortality", "pandemic disease", "pilot test", "population health", "post intervention", "preservation", "severe COVID-19", "theories", "unvaccinated", "uptake", "vaccination outcome", "vaccine acceptance", "vaccine hesitancy" ], "approved": true } }, { "type": "Grant", "id": "10633", "attributes": { "award_id": "75N93022C00052-0-9999-1", "title": "ADJUVANT COMPARISON AND CHARACTERIZATION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 3299681, "principal_investigator": { "id": 7241, "first_name": "BALI", "last_name": "PULENDRAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms in the context of Sars-CoV-2 vaccines.", "keywords": [ "Adjuvant", "COVID-19 vaccine", "Data Analyses", "Fingerprint", "Goals", "Human", "Immune", "Immunologics", "Mus", "Organoids", "Side", "Tissues", "Tonsil", "Vaccine Antigen", "Work", "adaptive immune response", "clinically relevant", "data management", "programs" ], "approved": true } }, { "type": "Grant", "id": "8792", "attributes": { "award_id": "1G20AI167410-01", "title": "Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-16", "end_date": "2023-02-28", "award_amount": 3299716, "principal_investigator": { "id": 24591, "first_name": "Karen E", "last_name": "Kim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "The Howard Taylor Ricketts Laboratory (HTRL) is a state-of-the-art Regional Biocontainment Laboratory on the Argonne National Laboratory (ANL) campus in DuPage County, Illinois. Located twenty-five miles southwest from the University of Chicago campus, ANL is a federally (Department of Energy) owned site operated by the University of Chicago (UCHICAGO LLC). HTRL is a CDC certified facility owned by the University of Chicago and operated by the Department of Microbiology. Biosafety training and surveillance program involving classroom and laboratory activities ensures that staff, students and fellows comply with state and federal regulations to safely operate facilities and experiments with RG2, RG3 and Select Agent pathogens. The HTRL construction was completed in 2008. Over the last 13 years, the HTRL has hosted research programs studying the bacterial species Yersinia, Brucella, Coxiella, Rickettsia, Bacilli, MRSA and other ESKAPE organisms, as well as viral pathogens including low and highly pathogenic influenza, DENGUE and more recently SARS-CoV2. The facility currently hosts research program on Plague, Anthrax and MRSA, as well as a Core Research Facility for SARS-CoV2. The HTRL is the largest A-BSL3 holding facility in the region and regularly supports research from consortium institutions including UIC, Northwestern U and Loyola U. The HTRL is fulfilling its goal as a biomedical research facility that can rapidly respond to research needs and support biomedical research on emerging and re-emerging pathogens, discovery and testing of new therapeutics and vaccines. The building has been maintained in excellent working conditions and has been in constant use since its construction. However, with the swelling demands for BSL3 and ABSL3 space and research expertise, the development of new technologies for the study of infectious agents, this proposal is a request (i) to upgrade system components necessary to maintain biocontainment, temperature/humidity/pressurization requirements, and safe research operations, and (ii) to replace research equipment that have either outlived the intended useful life or no longer meet facility requirements.", "keywords": [ "2019-nCoV", "Anthrax disease", "Bacillus", "Biomedical Research", "Brucella", "Centers for Disease Control and Prevention (U.S.)", "Chicago", "County", "Coxiella", "Department of Energy", "Development", "ESKAPE pathogens", "Ensure", "Equipment", "Goals", "Humidity", "Illinois", "Infectious Agent", "Influenza", "Institution", "Laboratories", "Life", "Microbiology", "Operations Research", "Organism", "Pathogenicity", "Plague", "Regulation", "Research", "Research Support", "Rickettsia", "Site", "Students", "Surveillance Program", "Swelling", "System", "Temperature", "Testing", "Training Programs", "Universities", "Yersinia", "emerging pathogen", "experimental study", "laboratory experiment", "methicillin resistant Staphylococcus aureus", "new technology", "novel therapeutics", "novel vaccines", "pathogen", "pathogenic virus", "pressure", "programs", "research facility" ], "approved": true } }, { "type": "Grant", "id": "8741", "attributes": { "award_id": "1G20AI167348-01", "title": "Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-23", "end_date": "2023-02-28", "award_amount": 3299989, "principal_investigator": { "id": 24532, "first_name": "Karen Marie", "last_name": "Dobos", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Abstract: The realization that our national and global communities are at risk from intentional, incidental, or emergent release of an infectious disease catalyzed our nation's commitment to invest in national and regional biocontainment laboratories as part of our public health and emergency preparedness system. The foothills campus at Colorado State University is home to one of these regional biocontainment laboratories, the Rocky Mountain Regional Biocontainment Laboratory (RMRBL). This laboratory was built in 2007, opened in 2008, and was the first of 12 designated laboratories to operate with select agent use certification. In the 14 years since its opening, our facility has thrived as a center of biodefense and emerging infectious disease research, responding to threats from re-emergent diseases, such as tuberculosis, and emerging infectious diseases, such as Middle East Respiratory Syndrome coronavirus, Zika, and notably, Severe Acute Respiratory Syndrome Coronavirus 2. This facility is truly unique in its capacity as it supports BSL3/ASBL3 and BSL2 basic research of a large number of emerging and re-emerging pathogens, and at the same time, supports the GLP/GMP testing and manufacturing of products (diagnostic reagents, vaccines, and therapeutics) in a BSL3 environment. Despite the RMRBL's success and strengths, a sole reliance on institutional commitment and service charges to investigators to support the costs of 1) operational and safety requirements of the facility; 2) animal care facilities and husbandry dedicated to infectious diseases; and 3) specialized equipment upgrades and repairs, present a major challenge to this facility's ability to remain at the forefront of research in pathogens of high consequence. The proactive and professional management of the RMRBL, and strong extramural funding of infectious diseases research at Colorado State University have allowed us to navigate these challenges; however, the continued aging of the facility coupled with the major costs of modernization and major facility and specialized equipment upgrades threaten the sustainability of the RMRBLs capacity to support state-of-the-art infectious disease research. In this application, we propose three aims that respectively address the needs to 1) upgrade operational and safety requirements of the facility, 2) maintain animal care facilities and husbandry dedicated to infectious diseases, and 3) modernize specialized equipment via strategic investments. The specific items selected under each aim as a critical investment were selected via a prioritization process that sought input from the major RMRBL and institutional stake holders and were determined to have the greatest impact on uninterrupted and accelerated research on high-containment pathogens and response to infectious disease outbreaks.", "keywords": [ "2019-nCoV", "Address", "Aging", "Basic Science", "Certification", "Charge", "Colorado", "Communicable Diseases", "Communities", "Containment", "Coupled", "Diagnostic Reagent", "Disease", "Disease Outbreaks", "Emerging Communicable Diseases", "Environment", "Equipment", "Extramural Activities", "Funding", "Health care facility", "Home", "Infectious Diseases Research", "Investments", "Laboratories", "Middle East Respiratory Syndrome Coronavirus", "Modernization", "Process", "Readiness", "Research", "Research Personnel", "Risk", "Safety", "Services", "System", "Testing", "Therapeutic", "Time", "Tuberculosis", "Universities", "Vaccines", "ZIKA", "animal care", "biodefense", "cost", "emerging pathogen", "pathogen", "public health emergency", "repaired", "response", "success" ], "approved": true } }, { "type": "Grant", "id": "13480", "attributes": { "award_id": "75N95023D00027-0-759502300001-1", "title": "SECURE PLATFORMS SUPPORT FOR THE N3C DATA ENCLAVE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-28", "end_date": "2023-12-20", "award_amount": 3300000, "principal_investigator": { "id": 26481, "first_name": "BRIAN", "last_name": "ZAVERTNIK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1737, "ror": "", "name": "PALANTIR TECHNOLOGIES, INC.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C Data Enclave is a secure platform storing harmonized clinical data provided by more than 60 contributing members. The Enclave hosts over 670 million clinical observations on over 6.8 million persons, including over 2.2 million COVID cases, amounting to more than 7.8 billion rows of data. To protect privacy, this data consists only of limited data sets, de-identified data sets, and synthetic data sets; there is no personally identifiable information kept in the Enclave. The Enclave resides in the NCATS Secure Scientific Platforms Environment. The Environment is a specialized cloud-based data aggregation and analytics enclave that can integrate, manage, secure, and analyze any kind of scientific data, and provide secure, controlled access to internal and external collaborators. Within the Environment, multiple NIH ICs, Federal agencies, and Federal task forces integrate, manage, secure, and analyze all types of scientific data using dedicated platforms, and, equally importantly, make that data available in specific and controlled collaborations with each other and with external collaborators.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7810", "attributes": { "award_id": "3U54MD010724-05S1", "title": "Administration Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 23620, "first_name": "Michael", "last_name": "Sayre", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-22", "end_date": "2023-08-31", "award_amount": 3305591, "principal_investigator": { "id": 23621, "first_name": "MARK RICHARD", "last_name": "CULLEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The spread of COVID-19 across the world and throughout the United States has brought extant disparities in health care resources and capacity into new focus as the various health, economic, and social harms of COVID19 disproportionately fall upon under-invested communities. Ongoing limitations in testing capacity, medical infrastructure and resources, and strong community partnerships are leading to greater spread of COVID-19, more difficulty in balancing precautionary isolation vs economic decisions, and a lack of data to guide public health policies. At the same time, efforts to overcome these issues that are led by faraway groups without local knowledge or consent can not only result in the promotion of ineffective solutions over local needs, but can also perpetuate ongoing harms to health, social, and economic concerns. Therefore, solutions that aim to address COVID-19 public health capacity in under-resourced environments must include local resources, local consent, and ensure long-term capacity, shared equity, and data control for participants. Here, we propose to leverage pre-existing resources and partnerships between the Stanford School of Medicine & tribal affiliates to upgrade existing laboratory infrastructure for conducting COVID-19 diagnostic tests, health consultations, and tribe-wide public health data management and policy. This capitalizes on existing resources built with the Native BioData Consortium (NBDC)—an Indigenous-led research group- from its collaboration with the SPHERE Project 1 BioRepository for American Indian Capacity, Education, Law, Economics, and Technology (BRAICELET) center. The work proposed here was designed to result in a tribe-governed health resource being operational within 6 months to conduct COVID-19 diagnostic tests and monitoring on an ongoing basis for improved public health.", "keywords": [ "Address", "Affect", "American Indians", "Bioethics", "COVID-19", "COVID-19 pandemic", "Calibration", "Centers for Disease Control and Prevention (U.S.)", "Collaborations", "Communicable Diseases", "Communities", "Consent", "Consultations", "Data", "Detection", "Development", "Devices", "Diagnostic", "Diagnostic Reagent", "Diagnostic tests", "Disease Outbreaks", "Economics", "Education", "Ensure", "Environment", "Equilibrium", "FDA approved", "Face", "Future", "Goals", "Government", "Health", "Health Policy", "Health Resources", "Healthcare", "Indigenous", "Infection", "Infrastructure", "Knowledge", "Laboratories", "Laws", "Measures", "Medical", "Methods", "Monitor", "Morbidity - disease rate", "Northern Plains Tribe", "Participant", "Patients", "Policies", "Population", "Prevalence", "Privacy", "Protocols documentation", "Public Health", "Public Health Practice", "Readiness", "Research", "Resources", "Risk", "Running", "Safety", "Science", "Secure", "Serologic tests", "Site", "Symptoms", "System", "Technology", "Test Result", "Testing", "Teton Sioux Indian", "Time", "Training", "Translations", "Tribes", "United States", "Work", "base", "biobank", "biosignature", "combat", "community partnership", "data management", "data resource", "design", "electronic data", "equipment acquisition", "falls", "fitness", "health disparity", "health economics", "heart rate monitor", "improved", "innovation", "insight", "medical schools", "mortality", "multimodality", "pandemic disease", "patient privacy", "preservation", "programs", "research facility", "response", "seroconversion", "social", "tool", "tribal community", "tribal health", "tribal medicine", "web portal" ], "approved": true } }, { "type": "Grant", "id": "9292", "attributes": { "award_id": "3P30AI027767-32S1", "title": "Core C Clinical Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 13099, "first_name": "Eric William", "last_name": "Refsland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-23", "end_date": "2023-05-31", "award_amount": 3323570, "principal_investigator": { "id": 25029, "first_name": "MICHAEL J", "last_name": "MUGAVERO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "Alabama is ranked as the state most vulnerable to COVID-19 by the community vulnerability index, and among the bottom 5 states in meeting SARS-CoV-2 testing targets. COVID-19 case rates are 3-fold higher in several rural counties in Alabama relative to metropolitan areas like Birmingham, with SARS-CoV-2 testing percent positivity approaching or exceeding 20% in a majority of rural counties. Meaningful community engagement in developing and implementing SARS-CoV-2 testing programs is vital to proactively address social, ethical and behavioral considerations germane to underserved communities. University of Alabama at Birmingham (UAB) Center for AIDS Research (CFAR) investigators have long-standing relationships working with clinical, community, and public health agencies to conduct innovative HIV testing and prevention studies, and are poised to act swiftly in response to the COVID-19 pandemic. A Dynamic COVID-19 Community-Engaged Testing Strategy in Alabama (COVID COMET AL) will transfer vast community-informed HIV testing knowledge to address the urgent need for rapid scale-up of SARS-CoV-2 testing among underserved rural, socio-economically disadvantaged, and Black/African American populations. COVID COMET AL is grounded in the ADAPT framework for tailoring evidence-based public health interventions for new settings and populations, and includes Assessment, Preparation, and Implementation phases. In collaboration with well-established clinical and community testing partners, regional health education centers, and additional community-based organizations, CFAR investigators will work together with interdisciplinary scientists from across campus at UAB to conduct the following specific aims: Aim 1 (Assessment): Refine a data-driven, time-updated algorithm to identify the underserved rural counties most impacted by COVID-19 in Alabama, Aim 2 (Preparation): Use a communityengaged sequential mixed-methods approach to inform tailored adaptation and implementation of the COVID COMET AL strategy in highly impacted rural counties selected for implementation, Aim 3 (Implementation): Deploy the iteratively adapted COVID COMET AL strategy, which includes peer health advocates, community health workers, and venue based testing, in 3 highly impacted rural Alabama counties at a time, in two sequential waves, each lasting 6-months, and Aim 4: Evaluate the implementation process of COVID COMET AL in partnering with community stakeholders to maximize program reach, effectiveness, and sustainability. Using a quasi-experimental, paired, comparative time series study design, temporal change in SARS-CoV-2 testing percent positivity will be compared in the 6 implementation counties relative to 6 matched control counties as the primary outcome, with testing reach, time to return test results, and time to contact tracing as secondary outcomes. Evaluation of COVID COMET AL implementation grounded in the Interactive Systems Framework will inform dissemination of this dynamic, data-driven public health testing strategy to maximize impact in addressing disparities in underserved rural communities, and will also guide COVID-19 vaccination strategies", "keywords": [ "2019-nCoV", "AIDS prevention", "Acquired Immunodeficiency Syndrome", "Address", "Advocate", "African American", "Alabama", "Algorithms", "Americas", "Area", "Asians", "Behavioral", "COVID-19", "COVID-19 pandemic", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Collaborations", "Communities", "Community Health", "Community Health Aides", "Contact Tracing", "Country", "County", "Data", "Deep South", "Disease", "Effectiveness", "Epidemic", "Epidemiology", "Ethics", "Ethnic Origin", "European", "Evaluation", "Foundations", "Future", "Geography", "HIV", "Health", "Health education", "Human immunodeficiency virus test", "Individual", "Infrastructure", "Interview", "Knowledge", "Location", "Medical", "Methods", "Modeling", "Morbidity - disease rate", "Persons", "Phase", "Population", "Positioning Attribute", "Preparation", "Process", "Public Health", "Race", "Research", "Research Design", "Research Personnel", "Research Support", "Resources", "Risk Factors", "Rural", "Rural Community", "Scientist", "Series", "System", "Test Result", "Testing", "Time", "Training", "United States", "Universities", "Update", "Vulnerable Populations", "Work", "base", "combat", "community partnership", "comparative", "coronavirus disease", "design", "evidence base", "experience", "experimental study", "indexing", "infection rate", "innovation", "meetings", "metropolitan", "mortality", "novel virus", "pandemic disease", "peer", "primary outcome", "programs", "public health intervention", "racism", "response", "rural counties", "rural underserved", "scale up", "secondary outcome", "social", "social stigma", "socioeconomic disadvantage", "socioeconomics", "success", "uptake", "vaccination strategy" ], "approved": true } }, { "type": "Grant", "id": "10251", "attributes": { "award_id": "3G20AI167405-01S1", "title": "Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-22", "end_date": "2023-02-28", "award_amount": 3329737, "principal_investigator": { "id": 7425, "first_name": "William Paul", "last_name": "Duprex", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: The Center for Vaccine Research (CVR) investigators conduct research on BSL-3 Category A, B, and C priority pathogens that have an impact on the health of people around the world. This is facilitated by the integral NIAID supported Regional Biocontainment Laboratory (RBL) which provides biosafety level (BSL)-2 and animal (A)BSL-3 capabilities. CVR is the hub for infection biology at the University of Pittsburgh bringing together virologists, bacteriologists, biochemists, structural biologists and clinicians from a variety of disciplines who have a common goal of investigating the evolution and pathogenesis of emerging infectious diseases and biodefense pathogens. The center enables the acceleration of pre-clinical development of novel interventions such as vaccines, therapeutic antibodies and nanobodies, small molecule inhibitors and diagnostics for viruses and other infectious agents. In 2021 CVR received a $3.3 million award to support fixed and non-fixed equipment upgrades within the RBL (G20AI167405). In this supplement to the parent, we focus on addressing scientific deficits and concentrate on the lack of flexible ABSL-3 space, small animal bioimaging capabilities and revitalizing core, shared equipment. Multimodal bioimaging capabilities are integral elements in understanding how pathogens infect cells, tissues and animals in four-dimensions. In this supplement we will expand our bioimaging capabilities to small and medium sized animals to augment our active large animal programs. These upgrades will be integrated into the current G20 parent project making it very cost effective in terms of recommissioning the facility. This ensure the supplement is fully within the scope of the parental award. This will ensure the University of Pittsburgh RBL remains fit-for-purpose and emerging infectious disease response-ready for another fifteen years. The facility is considered essential research infrastructure by the University of Pittsburgh, for the region, the state and nation. CVR staff have made major contributions to the ongoing COVID-19 pandemic by leveraging their significant experience working on pathogens with pandemic potential in biocontainment. Maintaining well trained, response ready cohorts of infection biologists across nation is vitally important as pathogens will continue to emerge. This makes pandemic preparedness an essential element of the national research portfolio.", "keywords": [ "Acceleration", "Achievement", "Address", "Administrative Supplement", "Aging", "Animals", "Applications Grants", "Award", "Biological", "Biology", "COVID-19 pandemic", "Capital", "Categories", "Cells", "Cities", "Communities", "Confocal Microscopy", "Contractor", "Diagnostic", "Discipline", "Ecosystem", "Elements", "Emerging Communicable Diseases", "Ensure", "Equipment", "Evolution", "Ferrets", "Four-dimensional", "Funding", "Goals", "Health", "Human", "Hydrogen Peroxide", "Immunologics", "In Vitro", "Infection", "Infectious Agent", "Infectious Diseases Research", "Infrastructure", "Institution", "Intervention", "Knowledge", "Laboratories", "Leadership", "Molecular", "National Institute of Allergy and Infectious Disease", "Oryctolagus cuniculus", "PET/CT scan", "Paper", "Parents", "Pathogenesis", "Pathologic", "Pennsylvania", "Persons", "Public Health", "Publications", "Recording of previous events", "Research", "Research Infrastructure", "Research Personnel", "Resources", "Rodent", "Structural Biologist", "Therapeutic antibodies", "Time", "Tissues", "Toxin", "Training", "Translating", "Translational Research", "United States National Institutes of Health", "Universities", "Vaccine Research", "Vaccines", "Viral", "Virus", "Vision", "Work", "biodefense", "bioimaging", "cohort", "cost effective", "experience", "faculty research", "flexibility", "in vivo imaging system", "medical schools", "multimodality", "nanobodies", "novel", "operation", "pandemic disease", "pandemic preparedness", "parent project", "pathogen", "preclinical development", "priority pathogen", "programs", "recruit", "response", "small molecule inhibitor", "success", "vapor" ], "approved": true } }, { "type": "Grant", "id": "8674", "attributes": { "award_id": "1G20AI167408-01", "title": "Facility and Building System Upgrades Support for the Mason Biomedical Research Laboratory", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-23", "end_date": "2023-02-28", "award_amount": 3330000, "principal_investigator": { "id": 24446, "first_name": "Farhang", "last_name": "Alem", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 239, "ror": "https://ror.org/02jqj7156", "name": "George Mason University", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 239, "ror": "https://ror.org/02jqj7156", "name": "George Mason University", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "In 2002, the NIAID convened a Panel on Bioterrorism and its implications for Biomedical Research to determine key priorities and short- and long-term goals for biodefense research in the United States. In response to the panel’s recommendations, the NIAID provided funding for the construction of two National Biocontainment Laboratories and 12 Regional Biocontainment Laboratories (RBLs). These installations have been an important resource for the nation as facilities where cutting edge scientific research on emerging infectious diseases and biodefense pathogens can be safely carried out. The Biological Research Laboratory (BRL) at George Mason University (GMU) is one of the 12 RBLs, and went into operation in July of 2010. In the decade since it opened its doors, GMU investigators have used the BRL to study select agents, such as Francisella tularensis, Burkholderia pseudomallei, Yesrinia pestis, Bacillus anthracis, Venezuelan equine encephalitis virus, Eastern equine encephalitis virus and SARS-CoV-2, as well as other pathogens, including, HIV and HTLV-1. To continue building on the success of the BRL, we are looking to upgrade aspects of the building’s infrastructure, in addition to purchasing new caging and state-of-the-art equipment that can serve the needs of the scientific community focused on infectious disease research and fighting the next pandemic. The Specific Aims of the proposal are as follows: 1) Purchase of animal caging to expand the BRL’s ability to house various species, from rodents to non-human primates; 2) Replacement of the tissue digester; 3) Purchase of imaging equipment, including the Fuji Vevo and Mediso PET-CT; 4) Installation of an automated watering system for the animal holding rooms; 5) Replacement of hot water heaters.", "keywords": [ "2019-nCoV", "Animals", "Bacillus anthracis", "Biomedical Research", "Bioterrorism", "Burkholderia pseudomallei", "Communities", "Eastern Equine Encephalitis Virus", "Emerging Communicable Diseases", "Equipment", "Francisella tularensis", "Funding", "Goals", "HIV", "Human T-lymphotropic virus 1", "Image", "Infectious Diseases Research", "Infrastructure", "Laboratories", "Laboratory Research", "National Institute of Allergy and Infectious Disease", "Positron-Emission Tomography", "Recommendation", "Research", "Research Personnel", "Resources", "Rodent", "System", "United States", "Universities", "Venezuelan Equine Encephalitis Virus", "Water", "biodefense", "biological research", "fighting", "nonhuman primate", "operation", "pandemic disease", "pathogen", "replacement tissue", "response", "success" ], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1424, "count": 14236 } } }